Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer
Test the tumour for a broken DNA spell-checker; if it has one, immunotherapy before surgery melts most tumours and in the rectum can replace surgery altogether.
NICHE-2 (colon: 68% pCR, 100% 3-year DFS after 4 weeks of nivolumab + ipilimumab), the MSK dostarlimab rectal cohort and AZUR-1 (organ preservation), and ATOMIC (adjuvant atezolizumab, DFS HR 0.50). Universal MMR/MSI testing at diagnosis is the gate.
Pages like this
not linked directly; found by shared links- PersonAndrea Cercek
Shares AZUR-1, Dostarlimab, Immune checkpoint inhibitors, Colorectal cancer.
- PersonMyriam Chalabi
Shares NICHE-2, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Ipilimumab, Nivolumab.
- Key paperNICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients
Shares NICHE-2, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Ipilimumab, Nivolumab.
- TermImmuno-oncology (IO) and checkpoint blockade
Shares Atezolizumab, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Ipilimumab, Nivolumab.
- Key paperNICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Neoadjuvant / adjuvant / perioperative, Ipilimumab, Nivolumab.
- TrialCheckMate 8HW
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Ipilimumab, Nivolumab, Colorectal cancer.
- Key paperDostarlimab alone cures mismatch-repair-deficient rectal cancer without surgery or radiotherapy
Shares Dostarlimab, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Neoadjuvant / adjuvant / perioperative, Immune checkpoint inhibitors.
- IdeaA funded programme of organ-preservation trials to avoid radical surgery
Shares Dostarlimab, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Neoadjuvant / adjuvant / perioperative, Colorectal cancer.